Genes explain GLP‑1 response
New genetics work helps explain why obesity drugs work better for some people: a Nature study of nearly 28,000 people found variants tied to stronger GLP‑1 weight‑loss response, but those same variants also link to higher risk of gastrointestinal side effects. That finding helps predict who might get the biggest benefit — while other research warns GLP‑1 drugs and bariatric surgery can also cause modest muscle loss, so strength‑preserving habits matter alongside medication ( ).
Glucagon-like peptide 1 is a gut hormone your body releases after you eat, and one of its jobs is to tell your brain and stomach that enough food has arrived. Drugs like semaglutide copy that signal, so people feel full sooner and often eat less without white-knuckling every meal. (nature.com) That sounds simple, but the results are not. In a new Nature study published on April 8, 2026, researchers analyzed 27,885 people who took glucagon-like peptide 1 drugs and found big person-to-person differences in both weight loss and side effects. (nature.com) The key new clue sits in the drug’s docking site. The study found a protein-changing variant in the GLP1R gene, which helps build the glucagon-like peptide 1 receptor, and each copy of that variant was linked to an extra 0.76 kilograms of weight loss on treatment. (nature.com) The same paper also found that side effects are not random bad luck. Genetic variation in GLP1R and in GIPR, a gene tied to a second gut-hormone receptor, was linked to nausea or vomiting, and the GIPR signal showed up specifically in people using tirzepatide, which targets both receptors. (nature.com) That helps explain a familiar complaint in obesity clinics: two people can take the same shot, at similar doses, and one loses far more weight while the other quits because the bathroom and the nausea become unbearable. Nature’s news write-up says the work points toward predicting who gets the biggest payoff and who gets the roughest ride before treatment starts. (nature.com) The study does not mean genes are destiny. Scientific American notes that these variants explain only part of the spread in outcomes, which leaves room for dose, adherence, diet, activity, sleep, other medicines, and plain biology that current studies still do not capture well. (scientificamerican.com) There is another catch hiding inside the number on the scale. When people lose weight with glucagon-like peptide 1 drugs, they usually lose fat-free mass too, and a 2025 review in Current Opinion in Endocrine and Metabolic Research says the field is paying closer attention to unintended losses in skeletal muscle. (sciencedirect.com) That muscle issue is not unique to these drugs. Mass General Brigham’s June 2025 review says lean body mass falls with weight loss broadly, including after diet changes and bariatric surgery, because eating less energy usually also means taking in less protein and giving the body less raw material to hold onto muscle. (advances.massgeneral.org) The practical advice is old-fashioned and specific. Mass General Brigham says exercise and a high-protein diet have shown benefit in preserving bone and muscle during treatment, which means the futuristic part of this story is the gene test, but the day-to-day part is still protein, resistance training, and watching body composition instead of only pounds. (advances.massgeneral.org) So the picture getting clearer in April 2026 is this: the same DNA changes that can make a glucagon-like peptide 1 drug work better can also raise the odds that it feels worse. The next version of obesity treatment may look less like handing everyone the same pen and more like matching the drug, the dose, and the muscle-preserving plan to the person in front of you. (nature.com)
